Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab for Prevention of Cardiac Rejection in Pediatric Transplant
NCT00284531Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2003
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in heart transplant rejection, sponsored by Baylor College of Medicine. Started Oct 2003; status: terminated.
02
Drugs
daclizumab
03
Conditions
heart transplant rejection
Beyond the preview
Go deeper on NCT00284531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284531.